- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc stock price live, this page displays NASDAQ PRLD stock exchange data. View the PRLD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Prelude Therapeutics Inc real time stock price chart below.
What Is the Prelude Therapeutics Inc Stock Price Today?
The Prelude Therapeutics Inc stock price today is 5.520.
What Is the Stock Symbol for Prelude Therapeutics Inc?
The stock ticker symbol for Prelude Therapeutics Inc is PRLD.
Is PRLD the Same as $PRLD?
$PRLD is a common way to refer to the Prelude Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Prelude Therapeutics Inc Trade On?
Prelude Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Prelude Therapeutics Inc a Good Stock to Buy?
Determining whether Prelude Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Prelude Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PRLD quote. (ISIN: US74065P1012)
What Is the Prelude Therapeutics Inc Stock Price Today?
The Prelude Therapeutics Inc stock price today is 5.520.
What Is the Stock Symbol for Prelude Therapeutics Inc?
The stock ticker symbol for Prelude Therapeutics Inc is PRLD.
Is PRLD the Same as $PRLD?
$PRLD is a common way to refer to the Prelude Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Prelude Therapeutics Inc Trade On?
Prelude Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Prelude Therapeutics Inc a Good Stock to Buy?
Determining whether Prelude Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Prelude Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PRLD quote. (ISIN: US74065P1012)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.263
5.540
52 wk Range
0.730
5.540
Unusual trading volume
1/3
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.2635.540
52 wk Range
0.7305.540
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PRLD Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
5.167
Downside
-6.40%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
- Form 424B5 Prelude Therapeutics Inc For: 13 March
- Investing.com
- Form 8K Prelude Therapeutics Inc For: 15 April
- Investing.com
- Form 8K Prelude Therapeutics Inc For: 15 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prelude Therapeutics Inc SWOT Analysis
Strategic Outlook | Learn about Prelude's potential in the competitive oncology landscape, with key data readouts and an IND filing for KAT6A degraders on the horizon |
Market Valuation | Analyst price targets range from $1 to $5, with a consensus of $3.20, reflecting mixed expectations for this clinical-stage biotech company |
Financial Footing | Delve into PRLD's solid cash position of $77.3M, crucial for funding ongoing clinical trials despite minimal revenue in this pre-market phase |
Pipeline Progress | Explore Prelude Therapeutics' advancing cancer drug candidates, including PRT3789 and PRT7732, with promising early-stage results in targeted therapies |
Prelude Therapeutics Inc Earnings Call Summary for Q3/2025
- Prelude Therapeutics reported Q3 2025 EPS of -$0.26, surpassing forecasts of -$0.3697, with revenue of $6.5 million and stock closing at $1.35, up 0.37% in pre-market trading.
- The company secured $60 million from an Incyte deal with potential for up to $910 million in milestone payments, maintaining a cash position that funds development through 2027.
- Management announced a strategic reorganization focusing on R&D efficiency and capital allocation, with new product developments targeting clinical entry in 2026.
- CEO Chris Vaddi emphasized the company's commitment to 'science and discovery excellence,' with clinical developments for myeloproliferative neoplasms and ER-positive breast cancer.
- Prelude expects clinical data updates in 2027 and is exploring combination therapy strategies based on promising preclinical results that may accelerate development timelines.
Last Updated: 11/12/2025, 11:57 AM
Read Full TranscriptCompare PRLD to Peers and Sector
Metrics to compare | PRLD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPRLDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.6x | −3.4x | −0.5x | |
PEG Ratio | −0.16 | −0.09 | 0.00 | |
Price / Book | 6.6x | 4.2x | 2.6x | |
Price / LTM Sales | 37.5x | 71.0x | 3.2x | |
Upside (Analyst Target) | 13.6% | 69.3% | 45.7% | |
Fair Value Upside | Unlock | 2.7% | 4.8% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 5.167
(-6.40% Downside)
Earnings
Latest Release
Mar 10, 2026
EPS / Forecast
-0.20 / -0.13
Revenue / Forecast
5.6M / 20.5M
People Also Watch
FAQ
What Is the Prelude (PRLD) Stock Price Today?
The Prelude stock price today is 5.520 USD.
What Stock Exchange Does Prelude Trade On?
Prelude is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Prelude?
The stock symbol for Prelude is "PRLD."
What Is the Prelude Market Cap?
As of today, Prelude market cap is 453.110M USD.
What Is Prelude's Earnings Per Share (TTM)?
The Prelude EPS (TTM) is -1.293.
When Is the Next Prelude Earnings Date?
Prelude will release its next earnings report on May 12, 2026.
From a Technical Analysis Perspective, Is PRLD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Prelude Stock Split?
Prelude has split 0 times.
How Many Employees Does Prelude Have?
Prelude has 79 employees.
What is the current trading status of Prelude (PRLD)?
As of Apr 16, 2026, Prelude (PRLD) is trading at a price of 5.520 USD, with a previous close of 4.400 USD. The stock has fluctuated within a day range of 4.263 USD to 5.540 USD, while its 52-week range spans from 0.730 USD to 5.540 USD.
What Is Prelude (PRLD) Price Target According to Analysts?
The average 12-month price target for Prelude is 5.167 USD, with a high estimate of 6 USD and a low estimate of 4.5 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an -6.40% Downside potential.
What Is the PRLD Premarket Price?
PRLD's last pre-market stock price is 4.320 USD. The pre-market share volume is 202.000, and the stock has decreased by -0.080, or -1.820%.
What Is the PRLD After Hours Price?
PRLD's last after hours stock price is 5.500 USD, the stock has decreased by -0.020, or -0.360%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.